Merck & Co., Inc. (MRK) Financials
Key financial figures for Merck & Co., Inc. (Q3 2026).
Merck Q3 2026 sales rose 5% to $18.1 billion on KEYTRUDA/KEYTRUDA QLEX ($8.6 billion) and WINREVAIR ($694 million, up 93%), and full-year non-GAAP EPS guidance was narrowed and raised to $2.77 to $2.82. Worldwide sales were $18,085 million, up 5% (4% excluding exchange) from $17,276 million a year earlier. Pharmaceutical sales were $16,268 million (up 4%) and Animal Health was $1,676 million (up 4%). Merck said pharmaceutical growth benefited by approximately $550 million from the timing of purchases. KEYTRUDA/KEYTRUDA QLEX sales were $8,601 million (up 6%), including $830 million of KEYTRUDA QLEX. WINREVAIR reached $694 million (up 93% year over year), GARDASIL/GARDASIL 9 was $1,995 million (up 14%), and the newly acquired OHTUVAYRE added $184 million. On the outlook: Full-year 2026 outlook: worldwide sales of $66.8 billion to $67.3 billion (prior $66.3 billion to $67.3 billion); non-GAAP EPS of $2.77 to $2.82 (prior $2.66 to $2.76), including one-time charges of $3.62 per share for Cidara, $2.31 per share for Terns and $0.12 per share for the SciBrunch license; non-GAAP gross margin approximately 81% (unchanged); non-GAAP operating expenses of $42.4 billion to $42.9 billion (prior $42.0 billion to $42.7 billion); non-GAAP effective tax rate of 32.0% to 33.0% (prior 35.0% to 36.0%); share count approximately 2.48 billion. Figures are for Q3 2026, as Merck & Co., Inc. reported them.
- Revenue
- $18.1B
- Net Income
- $5.1B
- EPS
- $2.05
- Total Assets
- $132.8B
- Operating Cash Flow
- $6.6B
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $18.1B | $5.1B | $2.04 | $5.5B | |
| Q2 FY2026 | $16.6B | -$1.3B | -$0.54 | $4.5B | |
| Q1 FY2026 | $16.3B | -$4.2B | -$1.72 | $2.9B | |
| Q4 FY2025 | $16.3B | $3.0B | $1.19 | $1.8B | |
| Q3 FY2025 | $17.2B | $5.8B | $2.32 | $6.8B |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $64.9B | $18.3B | $7.28 | $12.4B | |
| FY2024 | $64.2B | $17.1B | $6.74 | $18.1B | |
| FY2023 | $60.1B | $365M | $0.14 | $9.1B |
Frequently asked questions
What was Merck & Co., Inc.'s revenue last quarter?
Merck & Co., Inc. reported revenue of $18.09 billion for Q3 FY2026, up 5.2% from the same period a year earlier.
Is Merck & Co., Inc. profitable?
Yes. Merck & Co., Inc. reported net income of $5.07 billion for Q3 FY2026, a net margin of 28.01% on revenue.
How much free cash flow did Merck & Co., Inc. generate?
Merck & Co., Inc. generated free cash flow of $5.52 billion in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Merck & Co., Inc. on SentiSense, with up to forty quarters and twenty fiscal years of history.